Thalidomide Research

Learn the Truth

Chemistry Meets Biology

Trent D. Stephens, PhD Anatomy, Microbiology

As the only known thalidomide embryopathy expert in the United States, Dr. Trent Stephens has met many thalidomide survivors born in the United States and other countries.

After examining a person and/or their medical records, Dr. Stephens offers his expert opinion regarding whether a person’s birth defects were likely caused by in utero exposure to thalidomide or by some other condition or syndrome.

Dr. Stephens taught Anatomy and Developmental Biology at Idaho State University for 30 years. His research on the normal and abnormal biological form produced approximately 100 papers and books. He has authored or co-authored fourteen books, including “Dark Remedy: the Impact of Thalidomide and its Revival as a Vital Medicine”

Genetic and Rare Diseases Information Center

According to the Genetic and Rare Diseases Information Center (part of the U.S. Department of Health and Human Services)

“Thalidomide embryopathy is a group of anomalies presented in infants as a result of in utero exposure (between 20-36 days after fertilization) to thalidomide…

Thalidomide embryopathy is characterized by phocomelia, amelia, forelimb and hand plate anomalies (absence of humerus and/or forearm, femur and/or lower leg, thumb anomalies). Other anomalies include facial hemangiomas, and damages to ears (anotia, microtia), eyes (microphthalmia, anophthalmos, coloboma, strabismus), internal organs (kidney, heart, and gastrointestinal tract), genitalia, and heart.

Infant mortality associated with thalidomide embryopathy is estimated to be as high as 40%.”


Get Involved



Join to be supported by fellow thalidomide survivors.


Help support our members
with your donation.